Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis

被引：0

作者：

Arnold, Douglas ^{[1
,2
]}

Kappos, Ludwig ^{[3
]}

Hauser, Stephen ^{[4
]}

Montalban, Xavier ^{[5
]}

Traboulsee, Anthony ^{[6
]}

Wolinsky, Jerry ^{[7
]}

Levesque, Victoria ^{[8
]}

Villoslada, Pablo ^{[8
]}

Belachew, Shibeshih ^{[9
]}

Model, Fabian ^{[9
]}

Hubeaux, Stanislas ^{[9
]}

Bar-Or, Amit ^{[10
]}

机构：

[1] McGill Univ, Montreal, PQ, Canada

[2] NeuroRx Res, Montreal, PQ, Canada

[3] Univ Basel, Univ Hosp Basel, Basel, Switzerland

[4] Univ Calif San Francisco, San Francisco, CA USA

[5] Vall dHebron Univ Hosp, Barcelona, Spain

[6] Univ British Columbia, Vancouver, BC, Canada

[7] UTHealth, McGovern Med Sch, Houston, TX USA

[8] Genentech Inc, San Francisco, CA USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Univ Penn, Philadelphia, PA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S6.002

引用

页数：3